Former Bristol-Myers Squibb VP Zola Horovitz named chairman following resignation of Jay Moorin as chairman, president and CEO of biotech company. Magainin Senior VP and CFO Michael Dougherty succeeds Moorin as president and CEO. Former Exec VP and Director of the Magainin Institute of Molecular Medicine Roy Levitt, MD, is named to the newly created position of chief operating officer. Moorin will pursue other interests
You may also be interested in...
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth